Pharmacies Colluding On Minimum Part D Rx Reimbursement, PCMA Tells FTC
This article was originally published in The Pink Sheet Daily
Executive Summary
PBM trade group says pharmacies may be tempted to stay out of PBM- or health insurer-sponsored Part D drug plan networks to give chain and independent pharmacy-sponsored plans an advantage. The group claims the National Community Pharmacists Association is encouraging "collusive activity."
You may also be interested in...
FTC's Comments On PBMs Are Unproductive, State Legislators Say
National Legislative Association on Prescription Drug Prices criticizes the Federal Trade Commission's recent comments on state bills that would mandate greater PBM transparency, claiming FTC ignores evidence of deceptive practices and the need for state regulation.
GSK's Nucala Is Significantly Overpriced, ICER Draft Report Finds
New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.
Deal Watch: Sanofi, Boehringer Swap Side Businesses
Busy week for AstraZeneca sees buyout of Acerta and acquisition of remaining Daliresp/Daxas worldwide rights from Takeda. Amgen and GSK undo their cancer drug alliances from 2009 and 2010, with all rights reverting to the big biotech.